Mumbai: Indian Ambassador to US Taranjit Singh Sandhu said that India and the US have a lot of expertise in healthcare, pharma, basic research, vaccine, diagnostics, devices, telemedicine, hospital administration, healthcare supplies.
“The Global Health Emergency has made it clear that ensuring equal, affordable, and timely access to healthcare products and technologies is a priority for all. Global pharma and healthcare industries bear an external responsibility to meet the current challenge,” he said at a virtual discussion titled ‘India-US Partnership in Healthcare & Medical Research virtual event.
On the Indo-US partnership between the COVID-19 pandemic, the Indian ambassador stated, “Indian pharma companies, which are world leaders in affordable low-cost drugs and vaccines, are also collaborating with US companies in vaccine development, therapeutics, and diagnostics.”
India is working with the US private sector in vaccine development. Indian and American companies and institutions have at least three collaborations for co-development and production of the COVID-19 vaccine.
Speaking on the long-standing partnership between India and the US in health and scientific research, he said that scientists and institutes from both countries are actively engaged in information exchange.
He said, “COVID 19 virtual network being developed under the Indo-US Science and Technology Endowment Fund (IUSTEF) allows Indian and American scientists and engineers to jointly undertake research activities and leverage existing infrastructure and financing mechanisms.”
“The US biopharma industry invested approximately US $ 102 billion in R&D in 2018, more than any other industry in the US. India has a large pool of scientists and researchers. In fact, over several decades, many Indian doctors, Scientists, and researchers have arrived in the United States. Distinguished the states and themselves. “